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Introduction 
The development of pulmonary fibrosis in polymyositis is 
not rare (l-3) particularly in polymyositis characterized by 
the presence of anti-Jo-l (antihistidyl-tRNA synthetase) 
antibodies (4) referred to as the ‘Jo-l syndrome’ or ‘anti- 
synthetase syndrome’ (5). These antibodies appear to be 
specific for polymyositis (6) and correlate strongly with the 
presence of interstitial lung disease (5). However, pulmon- 
ary fibrosis rarely precedes the clinical recognition of poly- 
myositis (3) and is an indicator of poor prognosis (1). We 
describe a case where interstitial lung disease preceded the 
diagnosis of polymyositis by 12 months, and describe pos- 
sible factors related to therapy which delayed the definitive 
diagnosis. 
Case Report 
A 66-year-old man presented with a 3 weeks’ history of 
fatigue, dry cough and dyspnoea on exertion. He had no 
previous illnesses and was a lifelong non-smoker. He was 
on no medication. Physical examination revealed a low 
grade pyrexia, resting tachypnoea, bi-basal crepitations on 
chest auscultation, and no finger clubbing. 
Resting arterial oxygen tension (PaO,) was reduced at 
9.3 kPa breathing room air, and arterial carbon dioxide 
tension (PaCO,) was 4.8 kPa. Pulmonary function tests 
showed a restrictive pattern on spirometry with forced 
expiratory volume in 1 s (FEV,) and forced vital capacity 
(FVC) both 51% of the predicted normal values. The 
transfer factor (DICO) was 46%. Laboratory investigations 
demonstrated a neutrophil leukocytosis (16 x IO9 l- ‘) with 
a normal eosinophil count, erythrocyte sedimentation rate 
(ESR) of 30mm hh’ and hypoalbuminaemia (serum 
albumin 23 g 1 -I). A chest radiograph (Plate 1) and com- 
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PLATE 1. Chest radiograph on initial presentation show- 
ing extensive bi-basal infiltrates. 
PLATE 2. CT thorax on initial presentation showing 
extensive bi-basal infiltrates, predominantly sub-pleural in 
distribution. 
puted tomographic (CT) scan (Piate 2) indicated bilateral 
interstitial pulmonary infiltrates. 
The patient continued to have intermittent pyrexias over 
the next 4 weeks despite empiric broad-spectrum antibiotic 
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FIG. 1. Creatine kinase activity from diagnosis of 
polymyositis to present. 
PLATE 3. Chest radiograph following 9 months of oral 
steroid therapy, indicating significant resolution. 
PLATE 4. CT thorax after 9 months of oral steroid 
therapy indicating substantial resolution but residual 
scarring persisting. 
therapy. Microbiological cultures yielded no organisms. 
Autoantibody screens, including antinuclear antibodies 
(ANA), rheumatoid factor and antineutrophil cytoplasmic 
antibodies (ANCA), were negative. HIV serology was nega- 
tive. Flexible fibre-optic bronchoscopy revealed thick clear 
secretions and diffuse mucosal oedema. Bronchoalveolar 
lavage fluid (BAL) indicated a significant increase in 
neutrophils (12% of cell yield). Trans-thorascopic lung 
biopsy indicated a non-specific interstitial pneumonitis 
without granulomata or angiopathy. He was commenced 
on high-dose prednisolone (60 mg) after which his pyrexia 
resolved and his dyspnoea improved. Over the next several 
months, improvements were noted in radiological appear- 
ances on CXR (Plate 3) and CT thorax (Plate 4). Improve- 
ments in pulmonary function were also observed, with 
FEV, increasing to 61%, FVC to 65% and transfer factor to 
52%. However, after 6 months of continuous prednisolone 
therapy he developed proximal muscle weakness which was 
considered to be related to his steroid therapy, despite a 
gradual reduction in prescribed steroids. His steroid dose 
was further reduced to 10mg daily. However, his muscle 
weakness increased, and he was hospitalized for investiga- 
tion. CXR appearances remained stable but creatine kinase 
activity of 3500 U l- ’ (normal range O-l 85 U 1 - I), electro- 
myography (EMG), skeletal muscle biopsy and the pres- 
ence of a positive anti-Jo-l antibody titre confirmed the 
diagnosis of polymyositis. ANA was retested at this time 
and was positive (1:400 dilution) with a nucleolar pattern. 
EMG confirmed a myopathic process without neuropathy. 
The muscle biopsy reported the presence of a light mixed 
inflammatory cell infiltrate extending from muscle fascia 
into muscle fascicles, intimately associated with degenerat- 
ing fibres. Some fibres had undergone frank necrosis and 
showed replacement by macrophages. Neither ragged red 
fibres nor inclusion bodies were present, nor were rimmed 
vacuoles or Nemalin rods. There was no evidence of selec- 
tive atrophy or selective hypertrophy. Myophospharylase, 
phosphofructokinase and cytochrome oxidase studies were 
normal. The overall appearances were those of a sub-acute 
inflammatory myopathic process consistent with polymy- 
ositis. His steroid dosage was increased and azathioprine 
commenced with reduction in creatine kinase activity and 
improvement in muscle power. Over the next 12 months, his 
polymyositis followed a relapsing course (Fig. 1) but his 
pulmonary infiltrates and lung function remained relatively 
unchanged. Cyclophosphamide, 100 mg daily, in place of 
azathioprine, resulted in remission of his polymyositis, 
normalization of creatine kinase activity and muscle 
strength, and no deterioration in pulmonary function. 
Discussion 
Polymyositis is an inflammatory condition of skeletal 
muscle with one-third of cases occurring between 45 and 60 
years of age (2). Clinical suspicion of polymyositis is high 
where muscle pain or tenderness is obvious, but these 
symptoms may only occur in 50% of cases (7). Sub-acute 
polymyositis is much more common with features of pro- 
gressive weakness and atrophy of proximal muscle groups. 
Laboratory investigation usually indicates elevated serum 
creature kinase activity but definitive diagnosis may depend 
upon a combination of clinical findings, electromyography 
and muscle biopsy. Several respiratory complications have 
been associated with polymyositis. Respiratory muscle 
weakness, reduction in lung volumes, basal atelectasis, 
aspiration pneumonia due to reduced cough reflex or 
involvement of pharyngeal muscles, respiratory failure 
due to hypoventilation, and adult respiratory distress 
syndrome have been reported (8,9). Pulmonary fibrosis may 
occur in 5-10% (3,lO) and the presence of anti-Jo-l anti- 
bodies increases this likelihood (3). This case is unusual 
in that dyspnoea due to pulmonary infiltrates was the 
presenting feature rather than muscle weakness or pain. 
This sequence of events is rare in polymyositis, even in the 
anti-Jo-l syndrome, where the diagnosis of polymyositis 
often precedes any pulmonary involvement. As the pul- 
monary infiltrates and respiratory symptoms were con- 
sidered to be due to a steroid-responsive cryptogenic 
fibrosing alveolitis, treatment with corticosteroids was 
appropriate, although this therapy may have delayed the 
diagnosis of polymyositis. The development of proximal 
muscular weakness during therapy was initially considered 
to be a result of chronic steroid therapy, and the correct 
aetiology only became clear when reduction of the steroid 
dosage led to worsening of muscle weakness. This clinical 
pattern suggested the presence of polymyositis which was 
subsequently confirmed. The presence of anti-Jo-l anti- 
bodies may explain the responsiveness of the pulmonary 
infiltrates to steroid therapy as the presence of this anti- 
body seems to suggest a more favourable response to 
steroids (5). 
We conclude that corticosteroid therapy, although suc- 
cessfully treating the pulmonary pathology, may have 
obscured the underlying diagnosis and delayed definitive 
therapy due to the unusual mode of presentation. Clinicians 
should therefore consider measuring serum creatine kinase 
and anti-Jo-l antibody when investigating atypical cases of 
interstitial lung disease. 
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